UBS Reiterates Buy on Symantec (SYMC) Following Announced Intentions to Acquire LifeLock (LOCK)
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Analyst Brent Thill commented, "Today, SYMC announced its intention to acquire LifeLock (LOCK), a provider of consumer ID and fraud protection services, for $2.3B, following initial Bloomberg reports that surfaced on 11/11. The $24/share offer implies a 16% premium to LOCK's closing price on 11/18, a 36% premium to LOCK's unaffected share price at 11/10, and 145% from LOCK's Feb lows. We note activist investor Elliott had accumulated a ~9% stake in Jun and remind investors Elliott was also a stakeholder in SYMC earlier this year."
Shares of Symantec closed at $23.75 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rite Aid (RAD)/Walgreens (WBA) Antitrust Concerns Doesn't Mean Deal is Dead, Says Deutsche Bank
- Bats Global Market (BATS) Stockholders Approve Merger Agreement with CBOE (CBOE)
- FTC not sold on Walgreens' plan to win nod for Rite Aid deal: Bloomberg
Create E-mail Alert Related CategoriesAnalyst Comments, Mergers and Acquisitions
Related EntitiesUBS, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!